ISRCTN ISRCTN89534625
DOI https://doi.org/10.1186/ISRCTN89534625
Submission date
08/05/2024
Registration date
10/05/2024
Last edited
10/01/2025
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
A cancer diagnosis and its ensuing treatments can cause long-term effects and may impact daily living even years after any treatment has stopped. Persons diagnosed with cancer and living beyond cancer treatments are called cancer survivors. Our study explores cancer survivors’ symptoms and problems up to ten years after their diagnosis. Our aim is to describe self-reported symptoms and problems experienced by cancer survivors between five and ten years post-diagnosis. Further, we will explore cancer-related factors that might help to predict long-term problems. To achieve our aims, we will use a survey to gather relevant data.

Who can participate?
Cancer survivors who have been treated in canton Fribourg at one of the hospital sites linked to Fribourg cantonal hospital (HFR). Participants must have a diagnose of breast, colorectal, lung or prostate cancer, or a lymphoma or myeloma. The date of their diagnosis must lie between one and ten years before the recruitment date. Study participants need to understand written French or German to complete the questionnaires. In this study we will apply no intervention to participants. Eligible study participants will receive study information and questionnaires by postal mail. If they agree to participate, they will complete the questionnaires online or on paper once; no follow-up assessment will be carried out.

What does the study involve?
Our survey will use the National Comprehensive Cancer Network patient assessment questionnaire to assess long-term problems and the Self-Administered Comorbidity questionnaire. Overall, participants will answer 52 questions, which will take about 20 minutes. Questions are related to physical symptoms (e.g. breathing, skin alterations, pain, fatigue), emotional symptoms (e.g. stress, depressive mood), financial challenges, return to work, and healthy behaviour. Comorbidities are for example cardiovascular diseases, high blood pressure, diabetes, arthritis, or other common chronic conditions. Study collaborators will collect 18 items in order to explore details related to cancer diagnosis, complications during initial treatment, and further participant characteristics from medical records. The study results will show how frequent cancer-related long-term symptoms are, and how severe they are respectively one to five and five to ten years after diagnosis. Further, we will perform calculations with treatment- and diagnosis-related information which are linked to later problems and symptoms. Cancer survivors are expected to live with long-term effects caused by their cancer. This survey study results will have the potential to inform future early interventions and support for cancer survivors.

What are the possible benefits and risks of participating?
Study participants will receive no personal benefit by participating in the study and no study-specific risks are expected. Eligible participants are free to decide to answer the questions or not. Study participants will provide insights on their cancer survivorship experience in a Swiss canton. This information may help to improve cancer survivorship care in this region, a fact that might be of benefit later for the participants.

Where is the study run from?
HFR Fribourg – cantonal Hospital (Switzerland)

When is the study starting and how long is it expected to run for?
March 2023 to December 2024

Who is funding the study?
HFR Fribourg and the Fondation fribourgeoise pour la recherche et la formation sur le cancer (Switzerland)

Who is the main contact?
Prof. Marika Bana, RN PhD, marika.bana@hefr.ch

Contact information

Prof Marika Bana
Scientific, Principal Investigator

Haute école de santé Fribourg
Route des Arsenaux 16a
Fribourg
1700
Switzerland

ORCiD logoORCID ID 0000-0002-9988-6299
Phone +41 26 429 60 67
Email marika.bana@hefr.ch
Dr Marc Küng
Public

HFR Fribourg - Hôpital cantonal
Case postale
Fribourg
1708
Switzerland

Phone +41 26 306 00 00
Email marc.kueng@h-fr.ch

Study information

Study designRetrospective cross-sectional survey
Primary study designObservational
Secondary study designCross sectional study
Study setting(s)Home, Medical and other records
Study typeOther, Quality of life
Participant information sheet 45436 PIS French Info-Brief_CSS-Fri-fr_V2.4-15.11.23.pdf
Scientific titleCancer Survivorship Survey - Fribourg
Study acronymCSS-Fri
Study objectivesOur primary objective is to describe the prevalence of self-reported cancer-related symptoms / problems reported by residents treated or still followed for cancer, assessed by study questionnaire and HFR (hôpital fribourgeois) medical record documentation one to five years, and five to ten years post-diagnosis. Our secondary objective is to define predictive factors for supportive care needs and duration of return to work / family duties caused by cancer and/or treatment long-term or delayed effects, to inform a future survivorship programme and to identify relevant patient-reported outcomes to evaluate its impact.
Ethics approval(s)

Approved 03/01/2024, Commission cantonale d'éthique de la recherche sur lêtre humain CER-VD (Av. de Achilly 23, Lausanne, 1012, Switzerland; +41 21 316 18 36; CER@vd.ch), ref: 2022-00837_2205

Health condition(s) or problem(s) studiedCancer survivors diagnosed with breast, colorectal, lung, prostate, lymphoma or myeloma
InterventionWe evaluate cancer survivors long-term problems and symptoms by applying the NCCN survivorship patient assessment complemented with additional questions on co-morbidities and medical characteristics related to diagnosis and cancer treatment. Participants can choose to complete the questionnaire online or in paper format. Medical information will be assessed from medical records.
Intervention typeOther
Primary outcome measureSummarize the most frequent cancer related symptoms and problems perceived by study participants, measured by questionnaire
Secondary outcome measuresExplore predictive factors related to long-term and late symptoms and/or problems measured using questionnaire and patient records
Overall study start date01/03/2023
Completion date31/12/2024

Eligibility

Participant type(s)Patient, Resident
Age groupAdult
Lower age limit18 Years
Upper age limit99 Years
SexBoth
Target number of participants600
Total final enrolment333
Key inclusion criteria1. Adult residents (18 years and older) treated at a site linked to the Fribourg cantonal hospital
2. Diagnosis of breast, colorectal, lung or prostate cancer
3. Diagnosis of myeloma or lymphoma
4. Cancer diagnosis one to five years ago
5. Cancer diagnosis five to ten years ago
6. Returned completed questionnaire
Key exclusion criteria1. Does not understand/speak French or German
2. Not treated at the HFR
3. Currently hospitalised for a cancer treatment
4. Currently under intravenous anticancer treatment
Date of first enrolment28/02/2024
Date of final enrolment31/05/2024

Locations

Countries of recruitment

  • Switzerland

Study participating centre

HFR Fribourg - Hôpital cantonal
Case postale
Fribourg
1708
Switzerland

Sponsor information

HFR Freiburg Kantonsspital
Hospital/treatment centre

Case postale
Fribourg
1708
Switzerland

Phone +41 26 306 00 00
Email Daniel.Betticher@liguessante-fr.ch
Website https://www.fr.ch/hfr/de/pub/dashfr/standorte/freiburg.htm
ROR logo "ROR" https://ror.org/00fz8k419

Funders

Funder type

Charity

Fondation fribourgeoise pour la recherche et la formation sur le cancer

No information available

HFR Freiburg Kantonsspital

No information available

HES-SO University of Applied Sciences and Arts Western Switzerland - Fribourg, School of Health Sciences

No information available

Results and Publications

Intention to publish date31/07/2025
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planPlanned publication in a peer-reviewed journal.
IPD sharing planThe datasets generated during and/or analysed during the current study are/will be available upon request from Marika Bana (marika.bana@hefr.ch)

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Participant information sheet in French
version 2.4
15/11/2023 10/05/2024 No Yes
Participant information sheet in German
version 2.4
15/11/2023 10/05/2024 No Yes
Protocol file version 3.0 22/11/2023 10/05/2024 No No

Additional files

45436 Protocol V3.0 22Nov2023.pdf
45436 PIS French Info-Brief_CSS-Fri-fr_V2.4-15.11.23.pdf
in French
45436 PIS German Info-Brief_CSS-Fri-dt_V2.4-15.11.23.pdf
in German

Editorial Notes

10/01/2025: Total final enrolment and IPD sharing plan added.
08/05/2024: Trial's existence confirmed by Commission cantonale d'éthique de la recherche sur lêtre humain CER-VD.